CellaVision AB : CellaVision appoints new CFO

                CellaVision AB : CellaVision appoints new CFO

CellaVision announced today that Magnus Blixt has been appointed Chief
Financial Officer (CFO), effective May 2, 2013.

Magnus Blixt will take overall responsibility for the Group's Finance and
Administration function and will be part of the management team. Magnus Blixt
holds an MBA, and has extensive experience in running small and medium sized
companies focusing business performance and process improvements. He most
recently held the position as Business Demand Manager at SKF AB. Previous
experience includes a position as CFO at SKF Polyseal Inc. in the U.S.,
Operations Manager and Business Controller at SKF Sealing Solutions ESP and a
number of economic and finance positions, including Rotaform AB.

Magnus Blixt succeeds Sven-Åke Henningsson, Member of the Board, who has been
Acting CFO since September 2012.

For further information please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Tel: +46708 33 77 82 | Epost: yvonne.martensson@cellavision.com

About CellaVision
CellaVision is an innovative, global medical technology company that develops
and sells its own leading systems for routine analysis of blood and other body
fluids in health care services. The analyses often constitute important
reference data for fast and correct diagnosis of illnesses, for example of
infections and serious cancers. CellaVision's products rationalize manual
laboratory work, and secure and support effective workflows and skills
development within and between hospitals. The company has leading-edge
expertise in image analysis, artificial intelligence and automated microscopy.
In 2012 sales were SEK 170 million and sales continue to increase, with a
growth target of at least 15 % per year over an economic cycle. CellaVision's
registered office is in Lund and the company has subsidiaries in the USA,
Canada and Japan. The share is listed on the Nasdaq OMX Stockholm, Small Cap
list. Read more at www.cellavision.com.

This information was released for public disclosure on April 19, 2013 at 8.25
am CET.

Press release as PDF


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: CellaVision AB via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.